The DONIMI trial showed that the combination of neoadjuvant ICB with domatinostat was feasible and that the IFN-γ signature score in a baseline tumor biopsy was associated with pathologic response to neoadjuvant ICB. This evidence concerns the gene IFNG and neoplasm.